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Nives Pećina-Šlaus1,2* and Marko Pećina3Abstract
The development of new approaches based on wide profiling methods in studying biological and medical systems
is bringing large amounts of data on a daily basis.
The causes of complex diseases have been directed to the genome examination bringing formidable knowledge.
We can study genome, but also proteome, exome, transcriptome, epigenome, metabolome, and newcomers too
such as microbiome, connectome and exposome. The title of this editorial is paraphrasing the famous saying of
Victor Schlichter from Buenos Aires children hospital in Argentina who said “How unfair! Only one health, and so
many diseases”. Today there is indeed a whole lot of omics. We think that we are lucky to have all the omics
possible, but we also wanted to stress the importance of future holistic approach in integrating the knowledge
omics has rewarded us.
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The development of new approaches based on wide pro-
filing methods in studying biological and medical sys-
tems is bringing large amounts of data on a daily basis.
The causes of complex diseases have been directed to
the genome examination bringing formidable knowledge.
Cancer is a very complex disease. For a long time now
we know that genetics is standing behind cancer etiology
and genome examination is still primary approach in
studying all types of cancer. Nevertheless, other cellular
and biochemical levels are equally important. We can
study genome, but also proteome, exome, transcriptome,
epigenome, metabolome, and newcomers too such as
microbiome, connectome and exposome. The high-
throughput techniques that we nowadays employ have
changed cancer research [1]. They allow wide illustra-
tions of different levels of the specific problem.Review
The most common omics employed in molecular cancer
research are genomics -the analysis of genome structure
of organisms as a whole [2, 3]. Genome can be defi
ned as a complete genetic material of an organism the* Correspondence: nina@mef.hr
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unless otherwise stated.complete nucleotide sequence of its DNA. The human
genome is comprised of 3.2 billion nucleotides, but con-
tains only 23,500 protein-coding genes [4, 5]. Closely
connected to genomics are exomics and transcriptomics.
Exomes are the protein coding content of the genetic
code, the part of the genome formed by exons. The hu-
man exome consists of 180,000 exons, roughly 30 Mb of
DNA which is around 1-2 % of the total genome [6, 7].
In comparison to whole-genome sequencing meaning
decoding 3.2 billion nucleotides, exome sequencing is
much quicker, cheaper and far more comprehendable [8,
9]. Approximately 99 % of the human genome does not
code for a protein. Nevertheless, we know now that all
this amount of sequences are also important in perform-
ing different functions - some known and some un-
known [5]. The difference between exomics and
transcriptomics is basically the fact that transcriptome
encompases all RNA molecules synthesized by the
process of transcription, while, as we pointed out earlier,
the genomes and exomes are at the DNA sequence level
with relatively fixed nature [10]. The non-fixed nature of
transcriptome is reflected in different rates of transcrip-
tion e.i. synthesis of RNA molecules in a specific organ-
ism, tissue or cell type at a given time. Besides mere
presence of a given RNA molecule, transcriptome also
informs us on its amount at certain time and place.
Therefore it shows the expression of the information
encoded by the genome. The regulation of expressionen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stimuli but also as a response to environmental condi-
tions enabling cell to respond and adapt. Traditionally
transcriptome is analized by cDNA microarrays, but in
the last several years novel next-generation sequencing
platforms also known as RNA-seq techniques [11, 12]
are used.
The high through-put omics data in cancer are provid-
ing us with information often referred to in a number of
scientific papers as genomic landscapes of cancer [13,
14]. This excellent term encompasses multitude of spe-
cific genetic events and aims to illustrate the whole com-
plex cancer system [15]. Since we are talking about
landscapes there should be an atlas. Therefore, the Can-
cer Genome Atlas (TCGA) project began in 2006. by
collaboration of National Cancer Institute and National
Human Genome Research Institute. This endevour aims
to assemble all known changes for about 20 cancer types
[16]. In order to enable researchers to search, analyze
and validate important discoveries the data are publicly
accessible through the Cancer Genome Atlas (TCGA)
Data Portal. It is noteworthy to mention another import-
ant project searching for somatic alterations in cancer.
The Cancer Genome Project of the Wellcome Trust
Sanger Institute. This ongoing project is using the human
genome sequence and high-throughput mutation detec-
tion techniques to identify somatically acquired DNA se-
quence mutations in human tumours and tumour derived
cell lines. Through its resources, The Cancer Gene Census
and Catalogue of Somatic Mutations in Cancer (COS-
MIC), the project aims to systematically catalogue genes
mutated in human cancers thus identifying genes respon-
sible for cancer development [17–19].
The resulting integration of omics data showed both
subtype-specific genetic profiles but also similarities and
common changes shared among different cancer types.
We can now distinguish driver from passenger mutations,
a concept which can explain the great heterogeneity of
certain cancer types. The definition of a driver mutation is
the one that confers a selective growth advantage to the
tumor cell. Finding the driver mutations from passenger is
the major challenge in cancer genomics. As an example,
TCGA’s breast cancer project identified 30626 somatic
mutations by whole exome sequencing of 510 tumors
[16]. The somatic mutations included 28319 point muta-
tions, and 2302 insertions/deletions. With such large
number of aberrations it is hard to distinguish which are
key driver mutations and which signaling pathways play
major roles. Therefore recurrent mutations more fre-
quently found across specific tumors are proclaimed as
driver mutations. This is easily determined when the
number of mutations in a gene and the frequency of af-
fected gene is very high, as with TP53 or KRAS. Neverthe-
less, mutation frequency is not entirely reliable approachin driver genes identification. There are many genes
with more than one, but still relatively few mutations.
In these cases, methods based on mutation frequency
cannot reliably indicate which genes are drivers. Vogel-
stein et al. [14] state that the best way to identify driver
genes is through their pattern of mutations rather than
through their mutation frequencies. To classify a gene as a
driver of oncogenesis it is important to characterize the
gene as an oncogene or a tumor suppressor gene. The pat-
tern observed from many functional studies shows that
oncogenes are recurrently mutated at the same amino acid
positions, while tumor suppressor genes are character-
ized by protein truncating mutations. So, the pattern of
mutations characterizing an oncogene, is that >20 % of
the recorded mutations are at recurrent positions and
are missense, and to be classified as a tumor suppressor
gene, >20 % of the recorded mutations in the gene are
inactivating.
Passenger mutations encompasse all those neutral mu-
tations that have been accumulated in the original cell
before the oncogenic event occured [1]. They also hap-
pen along the way of clonal expansion and tumor pro-
gression but are not directly or indirectly involved in the
selective growth advantage of the cell in which they oc-
curred. They can occur during the preneoplastic phase
having no effect on the neoplastic process. Nevertheless,
they are very important for metastatic processes, for pa-
tients response to therapeutics and the clinical course of
the disease.
There are several computational models and algo-
rithms employed for functional consequence prediction
of detected mutations [15]. There are also computational
models and algorithms for data integration across cancer-
types and for data provided by different platforms. The
statistical assumptions used have been the subject of
debate, since it is difficult to determine a background mu-
tation rate for each tumor type. The development and
improvement of adequate computational methods for
interpreting genome-scale molecular information are ur-
gently needed today since the true meaning of compli-
cated data still needs to be elucidated.
To sum up what we have learned from genomic data
on cancer we can say that we know that in common
solid tumors an average of 33 to 66 genes display som-
atic mutations affecting their protein products. However,
there are tumor types that display many more muta-
tions, but also those that have only few mutated genes.
COSMIC’s latest release (v71; Sept 2014) describes 2 710
449 coding point mutations in over one million tumor
samples and across most human genes (28 977). About
95 % of these mutations are single-base substitutions of
which more than 90 % are missense mutations, whereas
the remaining are deletions or insertions of one or a few
bases. It is estimated that there are only about 138
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these, 74 are tumor suppressor genes and 64 are onco-
genes [14]. The complexity of cancer genomes is over-
whelming, displaying great genetic heterogeneity even
within the same histopathological tumor type. A palette
of driver mutations together with passenger mutations
make each individual tumor distinct. So how can we
make sense of such a great variability? The answer and
the light at the end of the tunnel lies in the fact that the
signal transduction pathways affected in different tumors
are similar. So, when the affected genes are placed into
signaling pathways, the cancer complexity is significantly
reduced [13]. The specific or shared pathways in signifi-
cant numbers of tumors can now be outlined. All of the
known driver genes function through 12 core signaling
pathways: WNT, NOTCH, Hedgehog, TGF-beta, MAPK,
STAT, PI3K, RAS, chromatin modification, transcrip-
tional regulation, DNA damage control and cell cycle-
apoptosis [14, 20].
The observed pathway similarities will provide oppor-
tunities to design tumor treatment targets and thera-
peutic discoveries. It seems that it is not crucial to
disable driver genes, but is sufficient to interfere with
the affected pathway in order to treat cancer. Therefore
we can now start designing treatments according to the
implicated pathway and not only to inhibit the action of
many specific individual proteins encoded by mutated
genes. Deep functional validation of candidate cancer
genes is still necessary before genomics information can
be introduced into clinical practice. It is important to
understand that not all somatic mutations within the
gene will be functionally equivalent. Clinical application
of genomics will soon refine the current cancer diag-
nostics and classification providing more accurate bio-
markers and personalized treatments. Diagnostics will
improve by development of new sets of specific tests for
each tumor type based on mutated genes and affected
signaling pathways.
In the past decade formidable data were brought by pro-
teomics, a field which can be defined as a large-scale study
of proteins, their functions and structures [21]. Proteomics
alone is a system science. Since proteins are functional
building blocks of cells, the information on proteome
of a given cell or tissue in health or disease, through
different phases of cell’s life, in interaction with the en-
vironment, etc. is a difficult but rewarding task to ac-
complish [22, 23]. The Human Proteome Project (HPP)
aims to map the entire human proteome and the in-
strumentation employed to do this is mass spectrom-
etry and bioinformatics [24, 25]. Human proteome
consists of 23,500 protein coding genes, but we have to
add different protein isoforms that are estimated to
million different protein isoforms, meaning million dif-
ferent proteins [26].Proteome profiles characteristic of specific cancer path-
ology will open new horizons in cancer research. Changed
cancer genome is reflected at the functional level which
means that proteome of a cancer cell is changed. Compara-
tion of cancer proteomes can be approached at two direc-
tions, absolute quantitation of observed changes and
relative approach where comparison of relative changes are
measured. Absolute amounts of proteins in a certain
sample are much harder to define and obtain, therefore
relative changes are usually measured in most proteomic
experiments.
One must not forget about epigenomics, the field that
counts all epigenetic changes, the changes, as the word
says, that are above the genome. The changes that are
above the nucleotide sequence of our genome include
molecular mechanisms of the modification of DNA and
the modulation of chromatin structure. Those mecha-
nisms can modify gene expression in differentiated cells
[27]. Methylation of cystein residues at specific positions
in the DNA is the premier molecular mechanism associ-
ated to epigenetic changes. Maintenance of methylation
patterns is important regulatory element and is closely
connected to genomic imprinting, a phenomenon where
expression of certain genes depends on whether they are
maternally or paternally inherited. Besides methylation, epi-
genetic mechanisms also include post-translational modifi-
cations of histones, chromatin remodeling and non-
protein coding RNA interfering pathways [28, 29]. The
study of epigenome aims to decipher and comprehend
these collaborative epigenetic modifications in order to
understand transcriptional regulation and establish pre-
cise gene expression programs.
Human tumors contain large numbers of epigenetic
changes affecting DNA or chromatin proteins. That epi-
genetic events may be involved in carcinogenesis is
reflected throught a large number of genes that are aber-
rantly expressed without being mutated. As the tumor
evolves those genes display changes in DNA methylation
or chromatin modification. Moreover, it has been shown
that a great number of driver genes encode proteins that
regulate chromatin remodeling.
The first discovery of epigenetic alterations in cancer
happened some 30 years ago when global DNA hypome-
thylation was reported in cancer in comparison to normal
cell [30, 31]. Global hypomethylation in cancer is referred
to a decrease in overall content of 5-methylcytosine found
in cancerous tissues. Hypomethylation usually targets re-
petitive sequences and is observed not only in cancer but
also in non-cancerous tissues exposed to chronic inflam-
mation. However, exactly how epigenetic alterations are
induced by exposure to inflammation is still not under-
stood. Later on promotor hypermethylation was discov-
ered to cause silencing of tumor suppressor genes. Recent
genomic research discovered mutations of epigenetic
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of IDH1 and IDH2 regulators were found in gliomas
which lead to loss of their function – genome wide
alterations of histone modifications. Mutations of other
epigenetic modifiers have also been identified usually
resulting in aberrant histone methylation [31].
Is the altered expression of epigenetic gene a driver or
a passanger event and are specific epigenetic changes
causes or consequences of tumorigenesis? Those are
questions that still need to be answered.
The difference between genetic and epigenetic changes
is that the genetic sequence is fixed while methylation is
plastic and dependable on microenvironment, patient
age, nutrient concentration etc. [14, 32]. Aberrant epi-
genetic events are frequently observed in early-stage
cancers and in adenomas. Thus, epigenetic epidemiology
has great application in cancer prevention by identifying
risk factors and establishing markers of early disease [33].
One of the most important characteristics of epigenetic al-
terations is that they can be reversed. This characteristic
can serve us well in the development of epigenetic drugs
for the purpose of restoration of normal epigenome.
Candidates for epigenetic drugs are DNA demethylating
agents, inhibitors for histone methyltrasferases and his-
tone demethylases and proteins that recognize histone
modifications.
The newcomers in omics are very interesting too -
metabolomics - the study of the complete set of all metab-
olites in an organism, microbiomics - the study of the
microbes in our gut and body and how they might cause
certain conditions, connectomics- the study of connec-
tomes with ultimate goal to map all the neural connec-
tions of human brain, exposomics, defined as the totality
of exposures received by an individual during a lifetime.
A metabolome is defined as the complete set of all me-
tabolites in an organism. Metabolites are low molecular
weight molecules less than 2000 Da in size and are the in-
termediates and end-products of metabolism. Within this
context the metabolomics is the study of the complexity
and totality of small molecular metabolitic intermediates
[34, 35]. The metabolome in contrast to genome and
proteome is very dynamic and susceptible to quick
changes since it is influenced by environment, microbiota
and other different physiological stimuli. Therefore, in
contrast to genome and proteome, metabolome is difficult
to define. The main analytical techniques employed in
metabolomics are nuclear magnetic resonance spectros-
copy (NMR) and mass spectrometry (MS) usually mea-
sured from biofluids such as plasma and urine [36]. In
2007. human metabolome was described and the corre-
sponding Human Metabolome Database was established
[37]. Human metabolome consists of a great number of
endogenous and exogenous compounds. Endogenous be-
ing synthesized by the enzymes encodes by our genomeand exogenous represent foreign chemicals consumed by
our body that all have effects on metabolic fluxes and
metabolic pathways.
When talking about metabolomics we have to consider it
in relation to metabolic control theory also know as flow
theory formulated about 40 years ago by Kacser and Burns
[38]. The theory describes how metabolic fluxes and con-
centrations depend on enzyme amount and gene dose. It is
based on measuring changes in steady-state metabolite
concentrations and fluxes induced by parameter modula-
tion [39, 40]. The authors promoted the operational defin-
ition called the flux control coeffieient, the relative increase
in flux, divided by the relative increase in enzyme activity
that brought it about. The theory provided great improve-
ment in our understanding of the control of metabolism.
Actually, the hyperbolic-like relationship between enzyme
activity and flux seems to be valid for most of the networks
including complex networks, regardless their complexity
[41]. Fluxes through metabolic networks can be considered
as model quantitative trait, depending on all the genes cod-
ing and regulating the enzymes of the network [40].
Concentration is a key parameter for enzyme activity
and changes in expression of enzyme genes play a cen-
tral role in the physiology of the cell. It has been used to
describe the response of metabolic concentrations and
fluxes to infinitesimal changes in enzyme concentrations
and effectors [42].
All pathways are inter-related, some closely and others
more distantly, i.e. everything in a cell is connected. But
the closeness of the relationship can change as the cellu-
lar environment changes. This means that intermingling
pathways might come in and go out depending on the
conditions - which gene starts operating differently affect-
ing other gene expression. So, any enzyme in a biochem-
ical pathway can become rate limiting, thus controlling
metabolism [43, 44].
The metabolic theory also provides explanation for why
so many large-effect mutations are recessive. Kascer and
Burns hypothesized on methematical grounds and on the
basis of empirical data that the relationship between flux
through a long metabolic pathway and enzyme activity at
any sigle step in the pathway is a curve of diminishing
returns. If we view the organism as an enzyme system
consisting of a large array of catalysts organized into diver-
ging and converging pathways and resulting in a plow of
metabolites as Kascer and Burns stated themselves [45]
the recessivity of large-effect mutations can be explained
as a consequence of a diminishing relationship betweeen
flux through a metabolic pathway and enzymatic activity
at any step in the pathway [46]. For several years after the
flux theory was proposed, this method was little used, but
later on it was extended by a number of groups and ap-
plied to various systems [47]. Perhaps it should be redis-
covered in omics millieu, too.
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new field of microbiomics. Microbiome represents all
genomes of microorganisms (or microbiota) that sym-
biontically live in us or on us. The magnitude of human
microbiota is overwhelming. It consists of about 100 tril-
lion microbial cells ten times outnumbering human cells
[48, 49]. Additionally the number of genes in the micro-
biome may exceed the total number of human genes by
two orders of magnitude. Our microbial symbionts there-
fore have high influence on our biology. For instance
microbiomics are actively involved in the control of host
metabolism and immune system development. Human in-
testinal microbiota can be regarded as a new organ cap-
able of performing numberous biochemical processes.
Different microbiota inhabit different body sites and the
knowledge of composition of microbial communities at
specific site is important in order to recognize changes
due to diseases [50]. The typical approach in microbio-
mics study is to choose a marker gene present in all of the
investigated micororganisms and yet whose sequences are
variable enough to be able to distinguish taxonomies.
The marker gene of choice is small subunit ribosomal
RNA (16S rRNA) gene [51]. Enabled by low-cost, high-
throughput DNA sequencing and on the basis of 16S
rRNA sequences microbiomics is analyzing and collecting
thousands of microbial DNA sequences.
Another omics that is not directly related to cancer
research but nevertheless needs to be mentioned is con-
nectomics. Because it will definitely have implicationsFig. 1 The thinker by Auguste Rodin. Vast amount of knowledge needs intin central nervous system tumorigenesis and conse-
quences of it.
Discovery of structural and functional brain connectivity
at different spatiotemporal scales is brought by connec-
tomics. How the brain really functions as a whole is still
an enigma that connectomics aim to elucidate. From the
network(s) of billions of neurons and synapses, all the way
up to structural networks of cortical and subcortical
regions at brain’s macro scale everything is connected by
exchanging signals and influencing each other. The ex-
planation of this dynamic network of interactions will
yield vital data on neural pathways that underlie brain
function, behavior and also individual differences [52].
The Human Connectome Project aims to map all neural
connections within healthy individuals’ brains using neu-
roimaging methods (structural MRI, Resting-state func-
tional MRI (rfMRI), diffusion imaging (dMRI) and Task-
evoked fMRI). There are challenges connectomics face,
for example this integrative map cannot capture modula-
tory processes and there are also questions on individual
and temporal variability.
Another equally interesting newcomer is the exposome,
the omics that aims to encompass total environmental ex-
posures through person’s lifecourse from the conception
onwards. Exposome started as part of epidemiological re-
search where it was first introduced because of the need
to assemble environmental exposure data. Closely com-
plementing the genome, exposome is a compilation of
non-genetic exposures influencing human health.egration
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external sources which include radiation, chemical con-
taminants and pollutants in air and water, lifestyle fac-
tors, diet, occupation and medical interventions, noice,
vibrations and climate. Nevertheless, endogenous pro-
cesses like inflammation, oxidative stress, gut microbiota,
diseases and infections are equally important [53–55].
When adding wider social economic factors and mental
stress the challenge of exposomics’ impact on human
health is even greater [56]. The study of exposome is per-
formed by simultaneous measurment of a multitude of
biomarkers from both sources [57]. The standardization
of measurements is still a challenge. Nevertheless, the data
brought by exposomics will contribute to better under-
standing of etiologies of human diseases and prevention.
In todays view of disease etiologies it has been estimated
that the majority of chronic diseases are attributed to en-
vironmental factors meaning that they are caused by
exposome. One of the first attempts to measure early life
exposome is the setting up of HELIX project [58]. The
project aims to measure and integrate a wide range of
chemical and physical exposures during pregnancy and
infancy.
However, omics data may be highly variable and the
results can easily be misinterpreted. Even genomics that
has long been viewed as static have been shown to be
plastic and liable to the dinamical changes under the influ-
ence from for example the environment. Another angle
that can explain variabilty are different sample conditions,
experiment preparations, instrumentation that all may in-
fluence the variabilty of omics results.
The title of this editorial is paraphrasing the famous
saying of Victor Schlichter from Buenos Aires children
hospital in Argentina who said “How unfair! Only one
health, and so many diseases”. Today there is indeed a
whole lot of omics. I think that we are lucky to have all
the omics possible, but I also wanted to stress the import-
ance of future holistic approach in integrating the know-
ledge omics has rewarded us (Fig. 1). In molecular biology
and molecular medicine one tends to compartmentalize
the knowledge obtained at different levels. In our opinion
this is not the deliberate action, but rather the conse-
quence of very elaborate and sophisticated methods of
data and information obtaining and also because of the
fact that the field is still young. A lot of work is still ahead
for the scientific community in analyzing and interpreting
the data we have collected and in application of omics in
clinical environment and diagnosis. Especially promising
is the understanding of the development of cancer as well
as the heterogeneity of this disease.
Conclusion
Different sophisticated, detailed, compex and elaborate
fields conditioned us to be experts only in singlecompartment of biology or even only in the specific level
of it. As science progressed through centuries it became
clear that one person cannont truly comprehend vastly
different fields and we concluded that in science there are
no more renaissance men. But in the light of new vast re-
search and high-throughput techniques we will have to go
back to the future and once again become renaissance
men understanding biology, biochemistry, bioinformatics
and biophysics. Only this time it is going to be much more
difficult. We have data but now we have to make sense of
it. Seems to us even harder to achieve.
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